Literature DB >> 8076937

Tyrosinemia type 1--complex splicing defects and a missense mutation in the fumarylacetoacetase gene.

H Rootwelt1, T Kristensen, R Berger, K Høie, E A Kvittingen.   

Abstract

Two mutations are reported in six tyrosinemia type 1 patients from northern Europe. In four patients, a G to A transition at nucleotide position 1009 (G1009-->A) of the fumarylacetoacetase (FAH) coding sequence caused aberrant splicing by introducing an acceptor splice site within exon 12, thereby deleting the first 50 nucleotides of this exon. The following exon-intron boundary was frequently missed, and a cryptic donor splice site within intron 12 caused a partial intron 12 retention of 105 bp. This point mutation alternatively gave a glycine 337 to serine substitution in instances of correct splicing. The mutation is rapidly detected by PvuII digestion of polymerase chain reaction (PCR)-amplified genomic DNA. Another mutation, g+5-->a in the intron 12 donor splice site consensus sequence (IVS12 g+5-->a), was found in five of the patients. This caused alternative splicing with retention of the first 105 nucleotides of intron 12, exon 12 skipping, and a combined deletion of exons 12 and 13. Rapid detection of this mutation is achieved by restriction digestion of PCR-amplified genomic DNA; a mismatch primer combined with the point mutation creates a Tru9I restriction site. One patient who was homozygous for the G1009-->A mutation had a chronic form of tyrosinemia. Three patients were combined heterozygotes for G1009-->A and IVS12 g+5-->a. Their clinical phenotypes varied from acute to chronic, indicating the impact of background genes and/or external factors on the presentation of tyrosinemia type 1.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8076937     DOI: 10.1007/bf00208276

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  20 in total

1.  Bidirectional solid-phase sequencing of in vitro-amplified plasmid DNA.

Authors:  T Hultman; S Bergh; T Moks; M Uhlén
Journal:  Biotechniques       Date:  1991-01       Impact factor: 1.993

2.  Direct PCR from CVS and blood lysates for detection of cystic fibrosis and Duchenne muscular dystrophy deletions.

Authors:  M E Balnaves; S Nasioulas; H H Dahl; S Forrest
Journal:  Nucleic Acids Res       Date:  1991-03-11       Impact factor: 16.971

3.  Automated DNA sequencing: ultrasensitive detection of fluorescent bands during electrophoresis.

Authors:  W Ansorge; B Sproat; J Stegemann; C Schwager; M Zenke
Journal:  Nucleic Acids Res       Date:  1987-06-11       Impact factor: 16.971

4.  Hereditary tyrosinemia type I. Self-induced correction of the fumarylacetoacetase defect.

Authors:  E A Kvittingen; H Rootwelt; P Brandtzaeg; A Bergan; R Berger
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

5.  The occurrence of hepatoma in the chronic form of hereditary tyrosinemia.

Authors:  A G Weinberg; C E Mize; H G Worthen
Journal:  J Pediatr       Date:  1976-03       Impact factor: 4.406

6.  Neurologic crises in hereditary tyrosinemia.

Authors:  G Mitchell; J Larochelle; M Lambert; J Michaud; A Grenier; H Ogier; M Gauthier; J Lacroix; M Vanasse; A Larbrisseau
Journal:  N Engl J Med       Date:  1990-02-15       Impact factor: 91.245

7.  Characterization of the human fumarylacetoacetate hydrolase gene and identification of a missense mutation abolishing enzymatic activity.

Authors:  Y Labelle; D Phaneuf; B Leclerc; R M Tanguay
Journal:  Hum Mol Genet       Date:  1993-07       Impact factor: 6.150

8.  Mutations of the fumarylacetoacetate hydrolase gene in four patients with tyrosinemia, type I.

Authors:  M Grompe; M al-Dhalimy
Journal:  Hum Mutat       Date:  1993       Impact factor: 4.878

9.  Two missense mutations causing tyrosinemia type 1 with presence and absence of immunoreactive fumarylacetoacetase.

Authors:  H Rootwelt; J Chou; W A Gahl; R Berger; T Coşkun; E Brodtkorb; E A Kvittingen
Journal:  Hum Genet       Date:  1994-06       Impact factor: 4.132

10.  Cloning and expression of the cDNA encoding human fumarylacetoacetate hydrolase, the enzyme deficient in hereditary tyrosinemia: assignment of the gene to chromosome 15.

Authors:  D Phaneuf; Y Labelle; D Bérubé; K Arden; W Cavenee; R Gagné; R M Tanguay
Journal:  Am J Hum Genet       Date:  1991-03       Impact factor: 11.025

View more
  6 in total

1.  Point mutations in the murine fumarylacetoacetate hydrolase gene: Animal models for the human genetic disorder hereditary tyrosinemia type 1.

Authors:  J L Aponte; G A Sega; L J Hauser; M S Dhar; C M Withrow; D A Carpenter; E M Rinchik; C T Culiat; D K Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-16       Impact factor: 11.205

2.  Geographical and Ethnic Distribution of Mutations of the Fumarylacetoacetate Hydrolase Gene in Hereditary Tyrosinemia Type 1.

Authors:  Francesca Angileri; Anne Bergeron; Geneviève Morrow; Francine Lettre; George Gray; Tim Hutchin; Sarah Ball; Robert M Tanguay
Journal:  JIMD Rep       Date:  2015-02-15

3.  Tyrosinaemia type I--de novo mutation in liver tissue suppressing an inborn splicing defect.

Authors:  Y T Bliksrud; E Brodtkorb; P A Andresen; I E T van den Berg; E A Kvittingen
Journal:  J Mol Med (Berl)       Date:  2005-03-10       Impact factor: 4.599

4.  Identification of a frequent pseudodeficiency mutation in the fumarylacetoacetase gene, with implications for diagnosis of tyrosinemia type I.

Authors:  H Rootwelt; E Brodtkorb; E A Kvittingen
Journal:  Am J Hum Genet       Date:  1994-12       Impact factor: 11.025

5.  Hereditary tyrosinemia type 1: novel missense, nonsense and splice consensus mutations in the human fumarylacetoacetate hydrolase gene; variability of the genotype-phenotype relationship.

Authors:  J K Ploos van Amstel; A J Bergman; E A van Beurden; J F Roijers; T Peelen; I E van den Berg; B T Poll-The; E A Kvittingen; R Berger
Journal:  Hum Genet       Date:  1996-01       Impact factor: 4.132

6.  The somatic FAH C.1061C>A change counteracts the frequent FAH c.1062+5G>A mutation and permits U1snRNA-based splicing correction.

Authors:  Daniela Scalet; Claudia Sacchetto; Francesco Bernardi; Mirko Pinotti; Stan F J van de Graaf; Dario Balestra
Journal:  J Hum Genet       Date:  2018-03-01       Impact factor: 3.172

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.